Volpara to Showcase AI Software for Breast Centers at NCBC 2024, Including Lunit INSIGHT for Early Detection
Volpara's online customer community reaches 1,000-member milestone
"NCBC comes at a time of great change for breast centers with new standards from the
Volpara and Lunit join forces
Volpara previously announced it entered into a Scheme Implementation Agreement with Lunit®. If the scheme is approved by Volpara shareholders and ultimately implemented, it is expected to be complete in Q2 2024. Regardless of the outcome of the scheme, a distribution agreement allows Volpara to sell Lunit's products immediately and offer a comprehensive suite that uses AI to enhance the mammography journey from screening to diagnosis.
Thriving Volpara customer community
Members of Volpara's Hive, the exclusive digital community for
Singing River addresses health disparities with Volpara
Hudson's presentation will review the clinical impact of making cancer risk assessment standard for every patient receiving a mammogram at four breast centers. The health system is located in a state that often ranks low in health outcomes and health literacy.
"Our comprehensive approach to care involves early identification and tailored support for high-risk patients. Genetic testing is a key tool for us," said Hudson. "Volpara Risk Pathways streamlines the overall process, helping patients receive the care they need for cancer prevention."
To see the latest software advancements for breast centers from Volpara visit Booth #303 at NCBC 2024.
About
Volpara is the preferred partner of leading healthcare institutions around the world. Our software is used in over 2,000 facilities by more than 5,600 technologists, impacting nearly 17 million patients globally. It helps providers conduct more than three million cancer risk assessments each year and can be deployed stand-alone or fully integrated with electronic health record systems, mammography reporting systems, imaging hardware, and genetic laboratories. Volpara holds the most rigorous security certifications and numerous patents and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in
For more information, visit www.volparahealth.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/volpara-to-showcase-ai-software-for-breast-centers-at-ncbc-2024-including-lunit-insight-for-early-detection-302090531.html
SOURCE